Algire et al., Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants, J. Natl. Canc. Inst., 1945, pp. 73-85, vol. 6. |
Angiolillo, et al., Human interferon-inducible Protein 10 is a poten inhibitor of angiogenesis in vovo, J. Exp. Med., 1995, pp. 441-446, vol. 74. |
Brawer et al., “Predictors of Pathologic Stage in Prostatic Carcinoma”, Cancer, Feb. 1, 1994, pp. 678-687, vol. 73, No. 3. |
Brem et al., “Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas”, Neurosurg., Mar. 1991, pp. 441-446, vol. 74. |
Cao, et al., “gro-B, a-C-X-C-Chemokine, Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice”, J. Exp. Med., Dec. 1995, pp. 2069-2077, vol. 182. |
Chen, et al., “A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors”, Cancer Research, Oct. 1, 1995, pp. 4230-4233, vol. 55. |
Clapp, et al., “The 16-Kilodalton N-Terminal Fragment of Human Prolactin is a Potent Inhibitor of Angiogenesis”, Endocrinology, Mar. 1993, pp. 1292-1299, vol. 133. |
Colman et al (editors), “Hemostasis and Thrombosis”, Basic Principles and Clinical Practice Second Edition, 2000 pp. 20 and 21, J.B. Lipincott Company Publishers, Philadelphia. |
Dameron et al., “Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1”, Science, Sep. 9, 1994, pp. 1582-1584, vol. 265. |
Folkman et al, “Long-term culture of capillary endothelial cells”, Proc. Natl. Acad. Sci. USA, Oct. 1979, pp. 5217-5221, vol., 76, No. 10. |
Folkman, Judah, “Tumor angiogenesis and tissue factor”, Nature Medicine, Feb. 1996, pp. 167-168, vol. 2, No. 2. |
Folkman, Judah, “What is the Evidence That Tumors Are Angiogenesis Dependent?”, Journal of the National Cancer Institute, Jan. 3, 1990, pp. 4-6, vol. 82, No. 1. |
Folkman, Judah, “Angiogenesis in cancer, vascular, rheumatoid and other disease”, Medicine, 1995, pp. 27-31, vol. 1, No. 1. |
Folkman et al., “Induction of angiogenesis during the transition from hyperplasia to neoplasia”, Nature, May 4, 1989, pp. 58-61, vol. 399. |
Folkman, Judah, “Tumor Angiogenesis: Therapeutic Implications”, The New England Journal of Medicine, Nov. 18, 1971, pp. 1182-1186, vol. 285, No. 21. |
Gavrieli et al., “Identification of Programmed Cell Death In Situ via Specific Labeling of Nuclear DNA Fragmentation”, The Journal of Cell Biology, 1992, pp. 493-501, vol. 119. |
Gimbrone et al., “Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea”, Journal of the National Cancer Institute, Feb. 1974, pp. 413-427, vol. 52, No. 2. |
Good et al., “A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin”, Proc. Natl. Acad. Sci. USA, Sep. 1990, pp. 6624-6628, vol. 87. |
Grant et al., “Two Different Laminin Domains Mediate the Differentiation of Human Endothelial Cells into Capillary-like Structures in Vitro”, Cell, Sep. 8, 1989, vol. 58. |
Gross et al., “Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro”, Proc. Natl. Acad. Sci. USA, May 1983, pp. 2623-2627, vol. 80. |
Gupta et al., “A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4”, Proc. Natl. Acad. Sci. USA, Aug. 1995, pp. 7799-7803, vol. 92. |
Hanlon et al., “Modeling Postradiation Prostate Specific Antigen Level Kinetics”, Cancer, Jul. 1, 1998, pp. 130-134, vol. 83, No. 1. |
Hodge et al., “A Recombinant Vaccinia Virus Expressing Human Prostate-Specific Antigen (PSA): Safety and Immunogenicity in a Non-Human Primate”, Int. J. Cancer, 1995, pp. 231-237, vol. 63. |
Holmgren et al., “Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression”, Nature Medicince, Feb. 1995, pp. 149-153, vol. 1, No. 2. |
Homandberg et al., “Heparin-Binding Fragments of Fibronectin are Potent Inhibitors of Endothelial Cell Growth”, Am. J. Path., Sep. 1985, pp. 327-332, vol. 120, No. 3. |
Hori et al., “Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibrblast Growth Factor”, Cancer Research, Nov. 15, 1991, pp. 6180-6184, vol. 51. |
Kandel et al., “Neovascularization Is Associated with a Switched to the Export of bFGF in the Multistep Development of Fibrosarcoma”, Cell, Sep. 20, 1991, pp. 1095-1114, vol. 66. |
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo”, Nature, Apr. 29, 1993, pp. 841-8444, vol. 362. |
Kim et al., “Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine”, Oncogene, 1998, pp. 3125-3135, vol. 17. |
Lilja et al., “Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with α1-Antichymotrypsin”, Clin. Chem., 1991, pp. 1618-1625, vol. 37, No. 9. |
Maione et al., “Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides”, Science, 1990, pp. 77-79, vol. 247. |
Millauer et al., “Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant”, Nature, Feb. 10, 1994, pp. 576-579, vol. 367. |
Muragaki et al., “Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones”, Proc. Natl. Acad. Sci. USA, Sep. 1995, pp. 8763-8767, vol. 92. |
Nelson et al., “Murine Epidermal Growth Factor (EGF) Fragment (33-43) Inhibits Both EGF- and Laminin- dependent Endothelial Cell Motility and Angiogenesis”, Cancer Research, Sep. 1, 1995, pp. 3772-3776, vol. 55. |
Nguyen et al., “Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane”, Microvascular Research, 1994, pp. 31-40, vol. 47. |
O'Reilly et al., “Endogeneous Inhibitors of Angiogenesis”, Proceedings of the American Assoc. for Cancer Research, Mar. 1996, p. 669, vol. 37 (Abstract only). |
O'Reilly et al., “Angiostatin induces and sustains dormancy of human primary tumors in mice”, Nature Medicine, Jun. 1996, pp. 689-691, vol. 2, No. 6. |
O'Reilly et al., “The Suppression of Tumor Metastases by a Primary Tumor”, Surigcal Forum, 1993, pp. 474-475, vol. XLIV. |
O'Reilly et al., “Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Caricnoma”, Cell, Oct. 21, 1994, pp. 315-328, vol. 79. |
O'Reilly et al., “Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth”, Cold Spring Harbor Symposia on Quantitative Biology, 1994, pp., 471-482, vol. LIX. |
Obeso et al., “Methods in Laboratory Investigation-A Hemangioendothelioma-Derived Cell Line: Its Use as a Model for the Study of Endothelial Cell Biology”, Laboratory Investigation, 1990, pp. 259-269, vol. 63, No. 2. |
Oh et al., “Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins”, Proc. Natl. Acad. Sci. USA, May 1994, pp. 4229-4233, vol. 91. |
Parangi et al., “Antiangiogenic therapy of transgenic mice impairs de novo tumor growth”, Proc. Natl. Acad. Sci. USA, Mar. 1996, pp. 2002-2007, vol. 93. |
Rastinejad et al., “Regulation of the Activity of a New Inhibitor of Angiogenesis by a Cancer Suppressor Gene”, Cell, Feb. 10, 1989, pp. 345-355, vol. 56. |
Rehn et al., “Identification of Three N-terminal Ends of Type XVII Collagen Chains and Tissue-specific Differences in the Expression of the Corresponding Transcripts”, The Journal of Biological Chemistry, 1995, pp. 4705-4711, vol. 270, No. 9. |
Rehn et al., “α1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen”, Proc. Natl. Acad. Sci. USA, May 1994, pp. 4234-3238, vol. 91. |
Riegman et al., “Characterization of the Human Kallikrein Locus”, Genomics, 1992, pp. 6-11, vol. 14. |
Robbins, Kenneth, “The Plasminogen-Plasmin Enzyme System”, Fibrinolysis, 1987, pp. 340-357. |
Sage et al., “Inhibition of Endothelial Cell Proliferation by SPARC is Mediated Through a Ca2+ -Binding EF-Hand Sequence”, Journal of Cellular Biochem., 1995, pp. 127-140, vol. 57. |
Sakamoto et al., “Inhibition of Angiogenesis and Tumor Growth by a Synthetic Laminin Peptide, CFPGYIGSR-NH2”, Cancer Research, Feb. 1, 1991, pp. 903-906, vol. 51. |
Sambrook et al, editors, “Molecular Cloning—A Laboratory Manual Second Edition”, Cold Spring Harbor Laboratory Press, 1989, pp. 17.37-17.41. |
Shackelford et al., “Biochemical properties and cellular effects of prostate specific antigen”, Proceedings of the American Association for Cancer Research, Mar. 1997, p. 428, vol. 38 (abstract only). |
Sokoll et al., “Prostate-Specific Antigen- It's Discovery and Biochemical Characterisitcs”, Urologic Clinics of NorthAmerica, May 1997, pp. 253-259, vol. 24, No. 2. |
Strieter et al., “Interferon γ-inducible Protein 10(IP-10), A Member of the C-X-C Chemokine Family, Is An Inhibitor of Angiogenesis”, Biochemical and Biophysical Research Communications, May 5, 1995, pp. 51-57, vol. 210, No. 1. |
Studier et al., “Use of T7 RNA Polymerase to Direct Expression of Cloned Genes”, Methods in Enzymology, 1990, pp. 60-89, vol. 185. |
Teicher et al., “Potentiation of Cytotoxic Cancer Therapies by TNP-740 Alone and With Other Anti-Angiogenic Agents”, Int. J. Cancer, 1994, pp. 920-925, vol. 57. |
Tolsma et al., “Peptides Derived from Two-Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity”, The Journal of Cell Biology, Jul. 1993, pp. 497-511, vol. 122, No. 2. |
Voest et al., “Inhibition of Angiogenesis In Vivo by Interleukin 12”, Journal of the National Cancer Institute, Apr. 19, 1995, pp. 581-586, vol. 87, No., 8. |
Wakui et al., “Tumour Angiogenesis in Prostatic Carcinoma with and without Bone Marrow Metastasis: A Morphometric Study”, Journal of Pathology, 1992, pp. 257-262, vol. 168. |
Weidner et al., “Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma”, American Journal of Pathology, Aug. 1993, pp. 401-409, vol. 143, No. 2. |
Weidner et al., “Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma”, The New England Journal of Medicine, Jan. 3, 1991, pp. 1-8, vol. 324, No. 1. |
Yang, Ning-Sun, “Gene Transfer into Mammalian Somatic Cells In Vivo”, Critical Reviews in Biochemistry, 1992, pp. 335-356, vol. 12, No. 4. |
Folkman, “Angiogenesis and its Inhibitors”, Important Advances In Oncology, J.B. Lippencott Company, 1985. |
O'Reilly et al., “Endostatin: An endogenous inhibitor of angiogenesis and tumor growth”, Cell, Jan. 24, 1997, pp. 277-285, vol. 88, No. 2 (Abstract only). |
Cohen et al., “Biological effects of prostate specific antigen as an insulin-like growth factor bindinprotein-3 protease”, Journal of Endocrinology, 1994, pp. 407-415, vol. 142. |
Beckner, M., Factors Promoting Tumor Angiogenesis, 1999, Cancer Investigations, vol. 17, pp. 594-623.* |
Gill et al., N. Eng. J. Med. 335:1261, 1996.* |
Mukhopadyay et al., Cancer Res., 55:6161, 1995.* |
Takigawa et al., Cancer Lett. 50:4131, 1990. |